Eye of Truth
Lobbyist Report for Cigna Corporation

Cigna Corporation

Health Services

701 PENNSYLVANIA AVENUE, NW SUITE 720 WASHINGTON, DC 20004

USA

Lobbying on the following issues:

MEDICARE/MEDICAID IMMIGRATION HEALTH ISSUES TRADE (DOMESTIC/FOREIGN) PHARMACY TAXATION/INTERNAL REVENUE CODE LABOR ISSUES/ANTITRUST/WORKPLACE

Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Issues related to the opioid epidemic, including H.R. 6, SUPPORT for Patients and Communities Act and and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to implementation of provisions in the Bipartisan Budget Act of 2018 that require increased integration of Medicare and Medicaid benefits by Dual-Eligible Special Needs Plans (D-SNPs) beginning in 2021. Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P).

-

Immigration reform proposals and H-1B visas.

-

Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, the Employer Relief Act of 2018, regarding a one-year delay of the Cadillac Tax. H.R. 4620, the the Protecting Families and Small Businesses Act of 2017, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically H.R. 3545, H.R. 5795, and H.R.6082, the Overdose Prevention and Patient Safety Act (OPPS Act), H.R. 6, the SUPPORT for Patients and Communities Act and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans. 21st Century Cures Act, section 4004, Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs, information blocking and interoperability.

-

Developments regarding Korean Trade Agreement (KORUS), China trade and tariffs, NAFTA.

-

Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to the proposed rule: Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.

-

Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017. H.R.5963, To delay the reimposition of the annual fee on health insurance providers until after 2020, regarding relief from the Health Insurance Tax. Issues related to the implementation of international tax provisions under P.L. 115-97, the Tax Cuts and Jobs Act. H.R. 88, A bill to change the boundaries of Shiloh National Park in Tennessee and issues related to the HIT and Cadillac tax.

-

Issues related to anti-trust and the Cigna-Express Scripts transaction. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans.

-

Lobbyists:

JULASON DAMATO, KRISTIN
DEVINE, BRENDAN
CANINO KALETA, JILL
MERSKI, RICHARD P
NONNEMAKER, KAREN LYNN
SCHWARTZ, DAVID
GALLAGHER, KATHRYN
LAWRENCE, COURTNEY

Foreign Entities:

Foreign Entity Name:
CACIF
Country :
GUATEMALA
Contribution :
$30,000



Lobbying on the following issues:

MEDICARE/MEDICAID DEFENSE LABOR ISSUES/ANTITRUST/WORKPLACE HEALTH ISSUES PHARMACY TRADE (DOMESTIC/FOREIGN) TAXATION/INTERNAL REVENUE CODE

-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and technical changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act. Issues related to H.R. 2115, Public Disclosure of Drug Discounts Act. -Issues related to H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability And Reporting (STAR) Act.

-

Pharmacy issues related to S. 1215 and H.R. 2500, the National Defense Authorization Act for Fiscal Year 2020.

-

Issues related to paid family leave and H.R. 1185/S. 463, the FAMILY Act and competition in health care.

-

-Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans and non-discrimination provisions. -21st Century Cures Act, section 4004, Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs, information blocking and interoperability. -Implementation of the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), as amended by the Affordable Care Act, the 21st Century Cures Act, and ERISA, including DOL proposed FAQs about Mental Health and Substance Use Disorder Parity Implementation. -Issues related to H.R. 861, the End Surprise Billing Act and "No Surprises Act" Discussion Draft. -Issues related to 42 C.F.R. Part 2, in H.R. 2062, The Overdose Prevention and Patient Safety Act and S. 1012, the the Protecting Jessica Grubbs Legacy Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets.

-

-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019.

-

Developments regarding Korean Trade Agreement (KORUS), China trade and tariffs, NAFTA.

-

-Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. -H.R. 748/S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40% ACA excise tax on certain employer-sponsored health insurance plans. -S.172/H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021. S.80, Jobs and Premium Protection Act, full repeal of the HIT.

-

Lobbyists:

JULASON DAMATO, KRISTIN
DEVINE, BRENDAN
CANINO KALETA, JILL
MERSKI, RICHARD P
NONNEMAKER, KAREN LYNN
SCHWARTZ, DAVID
GALLAGHER, KATHRYN
LAWRENCE, COURTNEY
SANTIVIAGO, SERGIO
Le Gette, Lisa Christine
Davis, Christopher
Katz, Emily A
Kline, Gary J

Foreign Entities:

Foreign Entity Name :
Mylan Holdings Limited
Country :
UNITED KINGDOM
Contribution :
$0
-
Foreign Entity Name :
Mylan NV
Country :
UNITED KINGDOM
Contribution :
$0
-



Lobbying on the following issues:

TAXATION/INTERNAL REVENUE CODE PHARMACY HEALTH ISSUES MEDICARE/MEDICAID DEFENSE TRADE (DOMESTIC/FOREIGN)

-Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. -H.R. 748/S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40% ACA excise tax on certain employer-sponsored health insurance plans. -S.172/H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021. S.80, Jobs and Premium Protection Act, full repeal of the HIT.

-

-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.

-

-Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans and non-discrimination provisions. -21st Century Cures Act, section 4004, Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs, information blocking and interoperability. -Implementation of the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), as amended by the Affordable Care Act, the 21st Century Cures Act, and ERISA, including DOL proposed FAQs about Mental Health and Substance Use Disorder Parity Implementation. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act. -Issues related to 42 C.F.R. Part 2, in H.R. 2062, The Overdose Prevention and Patient Safety Act and S. 1012, the the Protecting Jessica Grubbs Legacy Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First". -S.1323, the UNDERSTAND Act, legislation to improve the collection of social determinates of health (SDOH) data using ICD-10 Z-codes to track and report standardized definitions of SDOH affecting patients. -Issues related to utilization management and S.2546, The Safe Step Act of 2019, legislation to amend the Employee Retirement Income Security Act (ERISA) to require group health plans to streamline step therapy protocols and better ensure patients are able to access treatment.

-

-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and technical changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act. Issues related to H.R. 2115, Public Disclosure of Drug Discounts Act. -Issues related to H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability And Reporting (STAR) Act. -The Prescription Drug Pricing Reduction Act of 2019 (Chairman's Mark). -H.R. 2996, the More Efficient Tools to Realize Information For Consumers (METRIC) Act.

-

Pharmacy issues related to S. 1215 and H.R. 2500, the National Defense Authorization Act for Fiscal Year 2020.

-

Developments regarding Korean Trade Agreement (KORUS), China trade and tariffs, NAFTA.

-

Lobbyists:

JULASON DAMATO, KRISTIN
DEVINE, BRENDAN
CANINO KALETA, JILL
MERSKI, RICHARD P
NONNEMAKER, KAREN LYNN
Le Gette, Lisa Christine
Katz, Emily A
LAWRENCE, COURTNEY
SCHWARTZ, DAVID
Kline, Gary J
GALLAGHER, KATHRYN
SANTIVIAGO, SERGIO
Davis, Christopher

Foreign Entities:

Foreign Entity Name :
Fiat Chrysler Automobiles N.V.
Country :
UNITED KINGDOM
Contribution :
$0
-
Foreign Entity Name :
FCA Holdco B.V.
Country :
UNITED KINGDOM
Contribution :
$0
-
Foreign Entity Name :
FCA North American Holdings LLC
Country :
USA
Contribution :
$0
-



Lobbying on the following issues:

TAXATION/INTERNAL REVENUE CODE TRADE (DOMESTIC/FOREIGN) HEALTH ISSUES MEDICARE/MEDICAID DEFENSE PHARMACY

-Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. -H.R. 748/S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40% ACA excise tax on certain employer-sponsored health insurance plans. -S.172/H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021. S.80, Jobs and Premium Protection Act, full repeal of the HIT.

-

Issues related to draft Insurance legislation.

-

-Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans and non-discrimination provisions. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First". -S.1323, the UNDERSTAND Act, legislation to improve the collection of social determinates of health (SDOH) data using ICD-10 Z-codes to track and report standardized definitions of SDOH affecting patients.

-

-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and technical changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act. Issues related to H.R. 2115, Public Disclosure of Drug Discounts Act. -Issues related to H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability And Reporting (STAR) Act. -S.2543, The Prescription Drug Pricing Reduction Act of 2019. -H.R. 2296, the More Efficient Tools to Realize Information For Consumers (METRIC) Act.

-

Pharmacy issues related to S. 1215 and H.R. 2500, the National Defense Authorization Act for Fiscal Year 2020.

-

-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.

-

Lobbyists:

JULASON DAMATO, KRISTIN
DEVINE, BRENDAN
CANINO KALETA, JILL
MERSKI, RICHARD P
NONNEMAKER, KAREN LYNN

DUNN, JOE
Held the following Government positions
Chief of Staff, Rep. Jahana Hayes
Legislative Director and Senior Policy Advisor, Sen. Chris Murphy
Legislative Director, Senior Policy Advisor and Legislative Assistant, Rep. Anthony Weiner Chief of Staff, Rep. Jahana Hayes
Legislative Director, Senior Policy Advisor and Legislative Assistant, Rep. Anthony Weiner

SCHWARTZ, DAVID
Davis, Christopher
LAWRENCE, COURTNEY
Le Gette, Lisa Christine
GALLAGHER, KATHRYN
Kline, Gary J

Foreign Entities:

Foreign Entity Name :
FCA Holdco B.V.
Country :
UNITED KINGDOM
Contribution :
$0
-
Foreign Entity Name :
Fiat Chrysler Automobiles N.V.
Country :
UNITED KINGDOM
Contribution :
$0
-
Foreign Entity Name :
FCA North America Holdings, LLC
Country :
USA
Contribution :
$0
-



Lobbying on the following issues:

LABOR ISSUES/ANTITRUST/WORKPLACE DEFENSE HEALTH ISSUES TRADE (DOMESTIC/FOREIGN) PHARMACY MEDICARE/MEDICAID TAXATION/INTERNAL REVENUE CODE

Issues related to paid family leave and H.R. 1185/S. 463, the FAMILY Act.

-

Pharmacy issues related to the 2019 National Defense Authorization Act and implementation.

-

-Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, and non-discrimination provisions. -21st Century Cures Act, section 4004, Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs, information blocking and interoperability. -Implementation of the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), as amended by the Affordable Care Act, the 21st Century Cures Act, and ERISA, including DOL proposed FAQs about Mental Health and Substance Use Disorder Parity Implementation. -Issues related to H.R. 861, the End Surprise Billing Act.

-

Developments regarding Korean Trade Agreement (KORUS), China trade and tariffs, NAFTA.

-

-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act.

-

-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act.

-

-Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. -Issues related to the implementation of international tax provisions under P.L. 115-97, the Tax Cuts and Jobs Act. -H.R. 748/S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40% ACA excise tax on certain employer-sponsored health insurance plans. -S.172/H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021. S.80, Jobs and Premium Protection Act, full repeal of the HIT.

-

Lobbyists:

JULASON DAMATO, KRISTIN
DEVINE, BRENDAN
CANINO KALETA, JILL
MERSKI, RICHARD P
NONNEMAKER, KAREN LYNN
SCHWARTZ, DAVID
GALLAGHER, KATHRYN
LAWRENCE, COURTNEY
SANTIVIAGO, SERGIO

KLINE, GARY
Held the following Government positions
Senior Policy Advisor, Congressman Brian Bilbray (R-CA) Senior Policy Advisor, Congressman Brian Bilbray (R-CA) Senior Policy Advisor, Congressman Brian Bilbray (R-CA) Senior Policy Advisor, Congressman Brian Bilbray (R-CA) Senior Policy Advisor, Congressman Brian Bilbray (R-CA)


KATZ, EMILY
Held the following Government positions
Legislative Aide,U.S. Senator Ron Wyden Legislative Assistant,U.S. Senator Ron Wyden Health Policy Director,U.S. Representative Diana DeGette Health Policy Advisor,U.S. Senator Barbara Boxer Senior Health Policy Advisor,U.S. Senator Barbara Boxer Legislative Aide,U.S. Senator Ron Wyden Legislative Assistant,U.S. Senator Ron Wyden Health Policy Director,U.S. Representative Diana DeGette Health Policy Advisor,U.S. Senator Barbara Boxer Senior Health Policy Advisor,U.S. Senator Barbara Boxer Legislative Aide, U.S.Senator Ron Wyden Legislative Assistant,U.S. Senator Ron Wyden Health Policy Director,U.S. Representative Diana DeGette Health Policy Advisor,U.S. Senator Barbara Boxer Senior Health Policy Advisor,U.S. Senator Barbara Boxer Legislative Aide,U.S. Senator Ron Wyden Legislative Assistant,U.S. Senator Ron Wyden Health Policy Director,U.S. Representative Diana DeGette Health Policy Advisor,U.S. Senator Barbara Boxer Senior Health Policy Advisor,U.S. Senator Barbara Boxer Legislative Aide,U.S. Senator Ron Wyden Legislative Assistant,U.S. Senator Ron Wyden Health Policy Director,U.S. Representative Diana DeGette Health Policy Advisor,U.S. Senator Barbara Boxer Senior Health Policy Advisor,U.S. Senator Barbara Boxer


DAVIS, CHRIS
Held the following Government positions
Legislative Director and Senior Policy Advisor, Rep. Rick Boucher (D-VA) Intern, Rep. David Price (D-NC) Legislative Director and Senior Policy Advisor, Rep. Rick Boucher (D-VA) Intern, Rep. David Price (D-NC) Legislative Director and Senior Policy Advisor, Rep. Rick Boucher (D-VA) Intern, Rep. David Price (D-NC) Legislative Director and Senior Policy Advisor, Rep. Rick Boucher (D-VA) Intern, Rep. David Price (D-NC) Legislative Director and Senior Policy Advisor, Rep. Rick Boucher (D-VA) Intern, Rep. David Price (D-NC)

LE GETTE, LISA

Foreign Entities:

Foreign Entity Name:
Samvardhana Motherson Group (SMG)
Country :
INDIA
Contribution :
$30,000



Lobbying on the following issues:

MEDICARE/MEDICAID PHARMACY TAXATION/INTERNAL REVENUE CODE HEALTH ISSUES DEFENSE

-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Medicare and Medicaid Programs: Contract Year 2021 and 2022 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicaid Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4190-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -S.2543, The Prescription Drug Pricing Reduction Act of 2019. -Policies that impact public programs payments for high cost drugs including gene therapies.

-

-H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -Issues related to drug shortages, and pharmaceutical procurement processes.

-

-Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. -H.R. 748/S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40% ACA excise tax on certain employer-sponsored health insurance plans. -S.172/H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021. S.80, Jobs and Premium Protection Act, full repeal of the HIT.

-

-Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136., Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act. - Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. - Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans and non-discrimination provisions. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019; H.R. 3630, The No Surprises Act; and H.R. 5800, The Ban Surprise Billing Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First". -S.1323, the UNDERSTAND Act, legislation to improve the collection of social determinates of health (SDOH) data using ICD-10 Z-codes to track and report standardized definitions of SDOH affecting patients.

-

Pharmacy issues related to the National Defense Authorization Act for Fiscal Year 2021.

-

Lobbyists:

JULASON DAMATO, KRISTIN
DEVINE, BRENDAN
CANINO KALETA, JILL
MERSKI, RICHARD P
NONNEMAKER, KAREN LYNN
DUNN, JOE
SCHWARTZ, DAVID
GALLAGHER, KATHRYN
Kline, Gary J
Davis, Christopher
Le Gette, Lisa Christine
LAWRENCE, COURTNEY

Foreign Entities:

Foreign Entity Name :
FCA North America Holdings, LLC
Country :
USA
Contribution :
$0
-
Foreign Entity Name :
FCA Holdco B.V.
Country :
UNITED KINGDOM
Contribution :
$0
-
Foreign Entity Name :
Fiat Chrysler Automobiles N.V.
Country :
UNITED KINGDOM
Contribution :
$0
-



Lobbying on the following issues:

LABOR ISSUES/ANTITRUST/WORKPLACE MEDICARE/MEDICAID IMMIGRATION TRADE (DOMESTIC/FOREIGN) HEALTH ISSUES TAXATION/INTERNAL REVENUE CODE PHARMACY

Issues related to anti-trust and the proposed Cigna-Express Scripts transaction. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans.

-

Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Issues related to the opioid epidemic, including H.R. 6, SUPPORT for Patients and Communities Act and and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to implementation of provisions in the Bipartisan Budget Act of 2018 that require increased integration of Medicare and Medicaid benefits by Dual-Eligible Special Needs Plans (D-SNPs) beginning in 2021.

-

Immigration reform proposals and H-1B visas.

-

Developments regarding Korean Trade Agreement (KORUS), China trade and tariffs, NAFTA.

-

Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, the Employer Relief Act of 2018, regarding a one-year delay of the Cadillac Tax. H.R. 4620, the the Protecting Families and Small Businesses Act of 2017, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically H.R. 3545, H.R. 5795, and H.R.6082, the Overdose Prevention and Patient Safety Act (OPPS Act), H.R. 6, the SUPPORT for Patients and Communities Act and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans.

-

Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017. H.R.5963, To delay the reimposition of the annual fee on health insurance providers until after 2020, regarding relief from the Health Insurance Tax. Issues related to the implementation of international tax provisions under P.L. 115-97, the Tax Cuts and Jobs Act.

-

Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to the proposed rule: Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.

-

Lobbyists:

JULASON DAMATO, KRISTIN
DEVINE, BRENDAN
CANINO KALETA, JILL
MERSKI, RICHARD P
NONNEMAKER, KAREN LYNN
SCHWARTZ, DAVID
GALLAGHER, KATHRYN

LAWRENCE, COURTNEY
Held the following Government positions
Legislative Director, U.S. Representative Bill Cassidy
Legislative Correspondent and Staff Assistant, U.S. Representative Tom Price Legislative Director, U.S. Representative Bill Cassidy
Legislative Correspondent and Staff Assistant, U.S. Representative Tom Price

Foreign Entities:

Foreign Entity Name:
Samvardhana Motherson Group (SMG)
Country :
INDIA
Contribution :
$30,000



Money Spent:

Amount Client Government Entities

$2,360,000

Jan 22, 2019

FOURTH QUARTER REPORT

CIGNA CORPORATION

Office of Management & Budget (OMB)
HOUSE OF REPRESENTATIVES
White House Office
Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
U.S. Trade Representative (USTR)
SENATE
Commerce, Dept of (DOC)

$2,300,000

Jul 22, 2019

SECOND QUARTER REPORT

CIGNA CORPORATION

Office of Management & Budget (OMB)
HOUSE OF REPRESENTATIVES
White House Office
Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
U.S. Trade Representative (USTR)
SENATE
Commerce, Dept of (DOC)

$2,300,000

Oct 21, 2019

THIRD QUARTER REPORT

CIGNA CORPORATION

Office of Management & Budget (OMB)
HOUSE OF REPRESENTATIVES
White House Office
Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
U.S. Trade Representative (USTR)
SENATE
Commerce, Dept of (DOC)

$1,890,000

Jan 21, 2020

FOURTH QUARTER REPORT

CIGNA CORPORATION

Office of Management & Budget (OMB)
HOUSE OF REPRESENTATIVES
White House Office
Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
U.S. Trade Representative (USTR)
SENATE
Commerce, Dept of (DOC)

$1,760,000

Apr 22, 2019

FIRST QUARTER REPORT

CIGNA CORPORATION

Office of Management & Budget (OMB)
HOUSE OF REPRESENTATIVES
White House Office
Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
U.S. Trade Representative (USTR)
SENATE
Commerce, Dept of (DOC)

$1,480,000

Apr 20, 2020

FIRST QUARTER REPORT

CIGNA CORPORATION

Office of Management & Budget (OMB)
HOUSE OF REPRESENTATIVES
White House Office
Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
U.S. Trade Representative (USTR)
SENATE
Commerce, Dept of (DOC)

$1,460,000

Apr 22, 2019

THIRD QUARTER AMENDMENT

CIGNA CORPORATION

Office of Management & Budget (OMB)
HOUSE OF REPRESENTATIVES
White House Office
Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
U.S. Trade Representative (USTR)
SENATE
Commerce, Dept of (DOC)